<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03828227</url>
  </required_header>
  <id_info>
    <org_study_id>COLAGE C18-01 PRODIGE 66</org_study_id>
    <nct_id>NCT03828227</nct_id>
  </id_info>
  <brief_title>Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters</brief_title>
  <acronym>COLAGE</acronym>
  <official_title>Phase III Study to Evaluate the Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A national, multicenter, open-label, randomized phase III study. The trial aim is to
      determine the best therapeutic strategies according with the HRQoL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment cohort will be determined based on three parameters:

        -  Serum albumin level at baseline,

        -  ECOG Performance Status,

        -  Mini GDS.

      The &quot;Candidate&quot; group will be defined according to (all the following criteria must be
      fulfilled):

        -  Serum albumin level ≥ 30g/L,

        -  ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).

      The &quot;Non-candidate&quot; cohort group will be defined according to (at least one of those
      parameters is fulfilled):

        -  Serum albumin level &lt; 30g/L.

        -  And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).

      Patients in the &quot;Candidate group&quot; will be randomized to:

        -  OPTIMOX bevacizumab (arm A),

        -  Capecitabine + bevacizumab (arm B), in priority followed by FOLFOX-bevacizumab at first
           progression.

      Patients in the &quot;Non-candidate&quot; group cohort

      - Not randomized, follow-up patients receiving: capecitabine + bevacizumab
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with improvement of 10 points on the assessment of the quality of life at 6 months in the &quot;candidate group&quot;</measure>
    <time_frame>At 6 months</time_frame>
    <description>Improvement of 10 points compared to the score at inclusion on the following targeted dimensions: emotional functioning (4 items) and global health (2 items) (score from 6-30 with higher values representing better quality of life)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients amenable to salvage surgery</measure>
    <time_frame>until 58 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients amenable to second-line therapy,</measure>
    <time_frame>until 58 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient amenable to locoregional therapy</measure>
    <time_frame>until 58 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival,</measure>
    <time_frame>until 58 months</time_frame>
    <description>Progression-free survival is defined as time from date of first dose of study treatment to date of first documented PD or death due to any cause determined by the Investigator assessment in accordance to RECIST 1.1. Alive patients without progression will be censored at the last tumor assessment, either during study treatment period or during follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until 58 months</time_frame>
    <description>Overall survival, defined as the time between the date of the first dose of study treatment and the death date. Alive patients will be censored at the last date known to be alive, either during study treatment period or during follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Elderly Patients</condition>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>&quot;Candidate group&quot; OPTIMOX plus bevacizumab (Arm A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with :
Serum albumin level ≥ 30g/L,
ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).
Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Candidate group&quot; - Capecitabine-bevacizumab (Arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with :
Serum albumin level ≥ 30g/L,
ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).
This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Non candidate group&quot; - Capecitabine-bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with:
Serum albumin level &lt; 30g/L.
And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).
This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPTIMOX plus bevacizumab</intervention_name>
    <description>Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles
Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks (q2w)),
Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),
Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),
5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),
No 5-FU bolus.
then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)
Bevacizumab: 5 mg/kg IV (day 1, q2w),
FA: 400 mg/m² IV/2h (day 1, q2w),
5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)
No 5-FU bolus</description>
    <arm_group_label>&quot;Candidate group&quot; OPTIMOX plus bevacizumab (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine plus bevacizumab</intervention_name>
    <description>Bevacizumab: 7.5 mg/kg intravenous infusion [IV] (day 1; q3w),
Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w).</description>
    <arm_group_label>&quot;Candidate group&quot; - Capecitabine-bevacizumab (Arm B)</arm_group_label>
    <arm_group_label>&quot;Non candidate group&quot; - Capecitabine-bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent, and willing and able to comply with protocol
             requirements,

          2. Histologically proven colorectal adenocarcinoma,

          3. Confirmed metastatic disease,

          4. Patients with no detected dihydropyridine dehydrogenase (DPD) deficiency,

          5. No prior therapy for metastatic disease (in case of previous adjuvant chemotherapy,
             interval between the end of chemotherapy and relapse must be &gt; 6 months for
             fluoropyrimidine alone or &gt; 12 months for oxaliplatin-based chemotherapy,

          6. Duly documented unresectable metastatic disease i.e., not suitable for complete
             carcinological surgical resection,

          7. Age ≥ 75 years,

          8. ECOG PS 0-2,

          9. Hematological status: neutrophils ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L, and
             hemoglobin &gt; 9 g/dL,

         10. Adequate renal function: serum creatinine level &lt; 150 µmol/l, and creatinine clearance
             (Cockcroft and Gault or MDRD formula &gt; 30 mL/min),

         11. Adequate liver function: total bilirubin level &lt; 1.5 x upper normal limit (ULN), serum
             alkaline phosphatase (ALP) level &lt; 5 x ULN,

         12. Proteinuria &lt; 2+ (dipstick urinalysis) or ≤ 1g/24h,

         13. Regular follow-up feasible. The registered patient must be treated and followed at the
             participating center,

         14. Registration in France with the French National Health Care System (including
             dispositive PUMA (protection Universelle Maladie).

        Exclusion Criteria:

          1. History or evidence upon physical examination of CNS metastasis (e.g. non- irradiated
             CNS metastasis, seizure not controlled with standard medical therapy), unless
             adequately treated,

          2. Neuropathy grade &gt; 1,

          3. Patient with known dihydropyridine dehydrogenase (DPD) deficiency or history of severe
             and unexpected reactions to a fluoropyrimidine-containing regimen, or in case of
             clinically significant active heart disease or myocardial infarction within 6 months
             or if patient treated with sorivudine or its clinically related analogues, such as
             brivudine

          4. Uncontrolled hypercalcemia,

          5. Uncontrolled hypertension (defined as systolic blood pressure &gt; 150 mmHg and/or
             diastolic blood pressure &gt; 100 mmHg), or history of hypertensive crisis, or
             hypertensive encephalopathy,

          6. Medical history of other concomitant or previous malignant disease, except adequately
             treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of
             the skin, or cancer in complete remission for ≥ 5 years,

          7. History of arterial thrombotic and/or embolic event (e.g. myocardial infarction,
             stroke…) within 6 months prior to randomization,

          8. History of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal
             abscess or active GI bleeding within 6 months prior to randomization,

          9. History or evidence of inherited bleeding diathesis or significant coagulopathy at
             risk of bleeding,

         10. Major surgery (open biopsy, surgical resection, wound revision or any other major
             surgery involving entry into body cavity) or significant traumatic injury within the
             last 28 days prior to randomization, and/or minor surgical procedure including
             placement of a vascular device within 2 days of first study treatment,

         11. Concomitant administration of prophylactic phenytoin,

         12. Treatment with sorivudine or its chemically related analogues, such as brivudine,

         13. Patients with known allergy/hypersensitivity to any component of study drugs

         14. Concomitant unplanned anti-tumor treatment,

         15. Participation in another clinical trial with any investigational drug within 30 days
             prior to randomization,

         16. Other serious and uncontrolled non-malignant disease,

         17. Patient under guardianship, curatorship or under the protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisabeth CAROLA, MD</last_name>
    <phone>0140298500</phone>
    <email>Elisabeth.Carola@ghpso.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Line GARCIA LARNICOL, MD</last_name>
    <phone>0140298500</phone>
    <email>marie-line.garcia-larnicol@gercor.com.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Abbeville</name>
      <address>
        <city>Abbeville</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mathieu PAUWELS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hôpital sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michel GOZY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fayçal HOCINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Duchenne</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent BOURGEOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent BOURGEOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SAUDES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence SAUDES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Compiègne Noyon</name>
      <address>
        <city>Compiègne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Virginie SEBBAGH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCOG Picardie Groupe Hospitalier</name>
      <address>
        <city>Creil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth CAROLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth CAROLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe TOURNIGAND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe TOURNIGAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre geroges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leïla BENGRINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine REBISCHUNG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cécile LEYRONNAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois-Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Honorine GERVAIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Honorine GERVAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa CLAVEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Léa CLAVEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pauline RIES-GUYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Ile de France</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hélène DALL'OSTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérome DAUBA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme DAUBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric FRANCOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric FRANCOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Diaconnesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine DELBALDO</last_name>
    </contact>
    <investigator>
      <last_name>Catherine DELBALDO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel LOPEZ TRABADA ATAZ, Md</last_name>
    </contact>
    <investigator>
      <last_name>Daniel LOPEZ TRABADA ATAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LOUVET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu BACONNIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu BACONNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Malo</name>
      <address>
        <city>Saint-Malo</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anaïs BODERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

